EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

MAPK13 stabilization via m6A mRNA modification limits anticancer efficacy of rapamycin

Joohwan Kim, Yujin Chun, Cuauhtemoc B Ramirez, Lauren A Hoffner, Sunhee Jung, Ki-Hong Jang, Varvara I Rubtsova, Cholsoon Jang, Gina Lee

Journal of Biological Chemistry · 2023

DOI: 10.1016/j.jbc.2023.105175 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biological Chemistry, 2023. Verfasst von Joohwan Kim und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Molecular Genetics, Chao Family Comprehensive Cancer Center, School of Medicine, University of California Irvine, Irvi…. Hauptthemen laut MEDLINE: Sirolimus, RNA, Messenger, Adenosine, RNA Stability. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIAAA NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

N6-adenosine methylation (m6A) is the most abundant mRNA modification that controls gene expression through diverse mechanisms. Accordingly, m6A-dependent regulation of oncogenes and tumor suppressors contributes to tumor development. However, the role of m6A-mediated gene regulation upon drug treatment or resistance is poorly understood. Here, we report that m6A modification of mitogen-activated protein kinase 13 (MAPK13) mRNA determines the sensitivity of cancer cells to the mechanistic target of rapamycin complex 1 (mTORC1)-targeting agent rapamycin. mTORC1 induces m6A modification of MAPK13 mRNA at its 3' untranslated region through the methyltransferase-like 3 (METTL3)-METTL14-Wilms' tumor 1-associating protein(WTAP) methyltransferase complex, facilitating its mRNA degradation via an m6A reader protein YTH domain family protein 2. Rapamycin blunts this process and stabilizes MAPK13. On the other hand, genetic or pharmacological inhibition of MAPK13 enhances rapamycin's anticancer effects, which suggests that MAPK13 confers a progrowth signal upon rapamycin treatment, thereby limiting rapamycin efficacy. Together, our data indicate that rapamycin-mediated MAPK13 mRNA stabilization underlies drug resistance, and it should be considered as a promising therapeutic target to sensitize cancer cells to rapamycin.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SirolimusRNA, MessengerAdenosineRNA StabilityAntibiotics, AntineoplasticNeoplasmsHumansMethyltransferasesCell Line, TumorMechanistic Target of Rapamycin Complex 1Gene Expression Regulation, NeoplasticMethylationDrug Resistance, NeoplasmAnimalsRNA Splicing FactorsCell Cycle Proteins

Stichwörter der Autor:innen

MAPK13RNA modificationRNA stabilitym(6)AmTORC1p38rapamycin

Substanzen

SirolimusRNA, MessengerMethyltransferasesAdenosineN-methyladenosineMechanistic Target of Rapamycin Complex 1METTL3 protein, humanAntibiotics, AntineoplasticWTAP protein, humanRNA Splicing Factors

Autor:innen und Institutionen

  • Department of Microbiology and Molecular Genetics, Chao Family Comprehensive Cancer Center, School of Medicine, University of California Irvine, Irvine, California, USA.
  • Department of Microbiology and Molecular Genetics, Chao Family Comprehensive Cancer Center, School of Medicine, University of California Irvine, Irvine, California, USA; Department of Biological Chemistry, Chao Family C…
  • Department of Biological Chemistry, Chao Family Comprehensive Cancer Center, School of Medicine, University of California Irvine, Irvine, California, USA.
  • Department of Biological Chemistry, Chao Family Comprehensive Cancer Center, School of Medicine, University of California Irvine, Irvine, California, USA; School of Biological Sciences, University of California Irvine,…
  • Department of Microbiology and Molecular Genetics, Chao Family Comprehensive Cancer Center, School of Medicine, University of California Irvine, Irvine, California, USA. Electronic address: ginalee@uci.edu.

Förderung

  • NCI NIH HHS
  • NIAAA NIH HHS
  • NIGMS NIH HHS
  • Mary Kay Ash Foundation
  • Comprehensive Cancer Center, University of California, Davis
  • National Research Foundation of Korea
  • U.S. Department of Defense
  • National Institutes of Health

Zitieren

APA

Kim, J., Chun, Y., Ramirez, C. B., Hoffner, L. A., Jung, S., Jang, K. H., Rubtsova, V. I., Jang, C., & Lee, G. (2023). MAPK13 stabilization via m6A mRNA modification limits anticancer efficacy of rapamycin. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2023.105175

Vancouver

Kim J, Chun Y, Ramirez CB, Hoffner LA, Jung S, Jang KH, et al. MAPK13 stabilization via m6A mRNA modification limits anticancer efficacy of rapamycin. Journal of Biological Chemistry. 2023. doi:10.1016/j.jbc.2023.105175

BibTeX
@article{Kim2023,
  author = {Kim, Joohwan and Chun, Yujin and Ramirez, Cuauhtemoc B and Hoffner, Lauren A and Jung, Sunhee and Jang, Ki-Hong and Rubtsova, Varvara I and Jang, Cholsoon and Lee, Gina},
  title = {MAPK13 stabilization via m6A mRNA modification limits anticancer efficacy of rapamycin},
  journal = {Journal of Biological Chemistry},
  year = {2023},
  doi = {10.1016/j.jbc.2023.105175}
}
Kostenlos starten →